Apyx Medical Inc (APYX) - Net Assets
Based on the latest financial reports, Apyx Medical Inc (APYX) has net assets worth $6.08 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($57.37 Million) and total liabilities ($51.28 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Apyx Medical Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.08 Million |
| % of Total Assets | 10.6% |
| Annual Growth Rate | 13.02% |
| 5-Year Change | -77.55% |
| 10-Year Change | -38.75% |
| Growth Volatility | 125.88 |
Apyx Medical Inc - Net Assets Trend (1995–2024)
This chart illustrates how Apyx Medical Inc's net assets have evolved over time, based on quarterly financial data. Also explore how large is Apyx Medical Inc's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Apyx Medical Inc (1995–2024)
The table below shows the annual net assets of Apyx Medical Inc from 1995 to 2024. For live valuation and market cap data, see Apyx Medical Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $14.34 Million | -46.75% |
| 2023-12-31 | $26.92 Million | -28.76% |
| 2022-12-31 | $37.79 Million | -30.02% |
| 2021-12-31 | $54.01 Million | -15.42% |
| 2020-12-31 | $63.86 Million | -10.38% |
| 2019-12-31 | $71.26 Million | -18.81% |
| 2018-12-31 | $87.77 Million | +298.37% |
| 2017-12-31 | $22.03 Million | -15.98% |
| 2016-12-31 | $26.22 Million | +12.04% |
| 2015-12-31 | $23.40 Million | +398.59% |
| 2014-12-31 | $4.69 Million | -77.99% |
| 2013-12-31 | $21.33 Million | -6.84% |
| 2012-12-31 | $22.89 Million | +3.52% |
| 2011-12-31 | $22.12 Million | +1.62% |
| 2010-12-31 | $21.77 Million | +2.89% |
| 2009-12-31 | $21.15 Million | +12.59% |
| 2008-12-31 | $18.79 Million | +11.89% |
| 2007-12-31 | $16.79 Million | +18.42% |
| 2006-12-31 | $14.18 Million | +42.64% |
| 2005-12-31 | $9.94 Million | +7.40% |
| 2004-12-31 | $9.26 Million | +24.25% |
| 2003-12-31 | $7.45 Million | +14.77% |
| 2002-12-31 | $6.49 Million | -7.27% |
| 2001-12-31 | $7.00 Million | +9.49% |
| 2000-12-31 | $6.39 Million | +6.32% |
| 1999-12-31 | $6.01 Million | -35.25% |
| 1998-12-31 | $9.29 Million | +317.51% |
| 1997-12-31 | $2.22 Million | +10.12% |
| 1996-12-31 | $2.02 Million | +389.98% |
| 1995-12-31 | $412.30K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Apyx Medical Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6672810000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $38.00K | 0.27% |
| Other Components | $92.08 Million | 648.02% |
| Total Equity | $14.21 Million | 100.00% |
Apyx Medical Inc Competitors by Market Cap
The table below lists competitors of Apyx Medical Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Synalloy Corporation
NASDAQ:ACNT
|
$125.57 Million |
|
Darwin AG
XETRA:7V0
|
$125.57 Million |
|
Lotte Himart
KO:071840
|
$125.59 Million |
|
Keyrus SA
PA:ALKEY
|
$125.61 Million |
|
Silicom
NASDAQ:SILC
|
$125.54 Million |
|
The Hi-Tech Gears Limited
NSE:HITECHGEAR
|
$125.51 Million |
|
Spring Valley Acquisition Corp. II Class A Ordinary Shares
NASDAQ:SVII
|
$125.48 Million |
|
Aspen Group Ltd
TA:ASGR
|
$125.46 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Apyx Medical Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 26,701,000 to 14,210,000, a change of -12,491,000 (-46.8%).
- Net loss of 23,463,000 reduced equity.
- New share issuances of 7,000,000 increased equity.
- Other factors increased equity by 3,972,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-23.46 Million | -165.12% |
| Share Issuances | $7.00 Million | +49.26% |
| Other Changes | $3.97 Million | +27.95% |
| Total Change | $- | -46.78% |
Book Value vs Market Value Analysis
This analysis compares Apyx Medical Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.65x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 32.32x to 7.65x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1995-12-31 | $0.09 | $3.06 | x |
| 1996-12-31 | $0.26 | $3.06 | x |
| 1997-12-31 | $0.26 | $3.06 | x |
| 1998-12-31 | $0.67 | $3.06 | x |
| 1999-12-31 | $0.43 | $3.06 | x |
| 2000-12-31 | $0.40 | $3.06 | x |
| 2001-12-31 | $0.47 | $3.06 | x |
| 2002-12-31 | $0.45 | $3.06 | x |
| 2003-12-31 | $0.55 | $3.06 | x |
| 2004-12-31 | $0.55 | $3.06 | x |
| 2005-12-31 | $0.62 | $3.06 | x |
| 2006-12-31 | $0.83 | $3.06 | x |
| 2007-12-31 | $0.95 | $3.06 | x |
| 2008-12-31 | $1.10 | $3.06 | x |
| 2009-12-31 | $1.19 | $3.06 | x |
| 2010-12-31 | $1.25 | $3.06 | x |
| 2011-12-31 | $1.25 | $3.06 | x |
| 2012-12-31 | $1.29 | $3.06 | x |
| 2013-12-31 | $1.21 | $3.06 | x |
| 2014-12-31 | $0.26 | $3.06 | x |
| 2015-12-31 | $0.84 | $3.06 | x |
| 2016-12-31 | $0.96 | $3.06 | x |
| 2017-12-31 | $0.70 | $3.06 | x |
| 2018-12-31 | $2.55 | $3.06 | x |
| 2019-12-31 | $2.09 | $3.06 | x |
| 2020-12-31 | $1.86 | $3.06 | x |
| 2021-12-31 | $1.56 | $3.06 | x |
| 2022-12-31 | $1.09 | $3.06 | x |
| 2023-12-31 | $0.77 | $3.06 | x |
| 2024-12-31 | $0.40 | $3.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Apyx Medical Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -165.12%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -48.78%
- • Asset Turnover: 0.74x
- • Equity Multiplier: 4.56x
- Recent ROE (-165.12%) is below the historical average (-24.17%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1995 | -37.38% | -2.79% | 1.53x | 8.73x | $-195.33K |
| 1996 | 20.16% | 5.44% | 1.92x | 1.93x | $205.28K |
| 1997 | 4.46% | 1.35% | 1.92x | 1.72x | $-123.28K |
| 1998 | -10.75% | -11.82% | 0.79x | 1.15x | $-1.93 Million |
| 1999 | -36.31% | -22.75% | 1.31x | 1.22x | $-2.79 Million |
| 2000 | 7.83% | 5.04% | 1.26x | 1.24x | $-138.74K |
| 2001 | 11.20% | 6.83% | 1.34x | 1.23x | $84.26K |
| 2002 | -7.93% | -4.14% | 1.46x | 1.31x | $-1.16 Million |
| 2003 | 9.15% | 4.12% | 1.79x | 1.24x | $-63.67K |
| 2004 | 16.33% | 7.38% | 1.86x | 1.19x | $586.34K |
| 2005 | 4.14% | 2.01% | 1.72x | 1.20x | $-573.95K |
| 2006 | 19.08% | 10.06% | 1.60x | 1.19x | $1.28 Million |
| 2007 | 14.30% | 8.34% | 1.53x | 1.12x | $721.40K |
| 2008 | 9.75% | 6.52% | 1.09x | 1.37x | $-47.00K |
| 2009 | 2.82% | 2.21% | 0.98x | 1.30x | $-1.52 Million |
| 2010 | -7.05% | -6.34% | 0.87x | 1.28x | $-3.71 Million |
| 2011 | 0.49% | 0.43% | 0.90x | 1.28x | $-2.10 Million |
| 2012 | 2.69% | 2.23% | 0.98x | 1.23x | $-1.67 Million |
| 2013 | -20.34% | -18.34% | 0.71x | 1.56x | $-6.47 Million |
| 2014 | -368.17% | -62.43% | 1.11x | 5.29x | $-17.75 Million |
| 2015 | -22.94% | -18.19% | 0.94x | 1.34x | $-7.71 Million |
| 2016 | -15.06% | -10.78% | 1.04x | 1.34x | $-6.57 Million |
| 2017 | -22.98% | -13.02% | 1.25x | 1.41x | $-7.27 Million |
| 2018 | 72.93% | 383.61% | 0.17x | 1.09x | $55.23 Million |
| 2019 | -27.65% | -69.79% | 0.33x | 1.19x | $-26.83 Million |
| 2020 | -18.67% | -42.93% | 0.37x | 1.16x | $-18.27 Million |
| 2021 | -28.25% | -31.27% | 0.71x | 1.28x | $-20.54 Million |
| 2022 | -61.69% | -52.09% | 0.86x | 1.38x | $-26.94 Million |
| 2023 | -70.08% | -35.75% | 0.66x | 2.97x | $-21.38 Million |
| 2024 | -165.12% | -48.78% | 0.74x | 4.56x | $-24.88 Million |
Industry Comparison
This section compares Apyx Medical Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,700,760,609
- Average return on equity (ROE) among peers: -82.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Apyx Medical Inc (APYX) | $6.08 Million | -37.38% | 8.44x | $125.55 Million |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $16.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
About Apyx Medical Inc
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and abla… Read more